AstraZeneca (LON:AZN) Given “Buy” Rating at Berenberg Bank

Berenberg Bank reissued their buy rating on shares of AstraZeneca (LON:AZN) in a report issued on Monday,Digital Look reports. The firm currently has a GBX 140 ($1.74) price objective on the biopharmaceutical company’s stock.

A number of other analysts also recently weighed in on AZN. JPMorgan Chase & Co. reiterated an “overweight” rating and set a £140 ($174.19) target price on shares of AstraZeneca in a research report on Friday, November 22nd. Shore Capital reissued a “buy” rating on shares of AstraZeneca in a report on Thursday, November 7th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and six have assigned a buy rating to the company. Based on data from MarketBeat.com, AstraZeneca currently has an average rating of “Moderate Buy” and a consensus price target of GBX 7,935.67 ($98.74).

AstraZeneca Stock Performance

Shares of LON AZN traded down GBX 10 ($0.12) during trading hours on Monday, reaching £111.70 ($138.98). 6,044,899 shares of the stock were exchanged, compared to its average volume of 46,410,563. The stock’s fifty day simple moving average is £105.88 and its 200 day simple moving average is £115.38. The firm has a market capitalization of £173.13 billion, a price-to-earnings ratio of 3,546.03, a P/E/G ratio of 0.86 and a beta of 0.17. AstraZeneca has a 52 week low of GBX 9,461 ($117.72) and a 52 week high of £133.88 ($166.58). The company has a debt-to-equity ratio of 84.97, a quick ratio of 0.59 and a current ratio of 0.89.

Insider Transactions at AstraZeneca

In related news, insider Tony Mok bought 1,500 shares of the company’s stock in a transaction that occurred on Tuesday, November 19th. The shares were bought at an average price of £126.80 ($157.77) per share, for a total transaction of £190,200 ($236,655.47). Also, insider Pascal Soriot purchased 20,000 shares of the firm’s stock in a transaction on Thursday, November 14th. The stock was bought at an average cost of £102.03 ($126.95) per share, with a total value of £2,040,600 ($2,539,007.09). Corporate insiders own 0.04% of the company’s stock.

AstraZeneca Company Profile

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.